* Guest Post by Genevieve Roch-Decter, CEO of Grit Capital*
5 Reasons LHS-CSE Could be a Buy Here:
Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF), a provider of high quality cannabis, announced that it has received the report of its independent directors regarding allegations made by Hindenberg Research in its report dated December 6, 2018(the "Short Seller Report").
Investigation into Principal Allegations Contained in Short Seller Report
Last year, the United States cannabis industry recorded massive growth and this is a trend that is just getting started. With new market opening and existing markets growing, the opportunities for cannabis companies are significant and this is an opportunity we have been closely watching.
The United States cannabis industry represents a significant growth opportunity and we have been monitoring the companies that are levered to this burgeoning market. During the last year, there has been a significant increase in the number of states that have legalized some form of legal cannabis and we are favorable on this trend.
The United States cannabis industry is one of the most exciting growth opportunities available for investors and we have been closely monitoring this burgeoning market. During the last year, the industry has recorded significant growth and the companies levered to this market have benefited from this growth.
2018 was a banner year for the United States cannabis industry and 2019 will most likely be even more significant. During the last year, we have seen several significant medical cannabis markets open on the East Coast of the United States and we expect these markets to record massive growth going forward.
Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com, a provider of high quality cannabis, today announced the launch of Zentient Labs, a line of premium hemp-based CBD products made from a proprietary formula of ultra-high quality CBD, nutraceuticals and vitamins that promote energy and focus for wellness seekers.